Search Results - "Ganta, Ranga Raman"

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase by Linga, Vijay Gandhi, Ganta, Ranga Raman, Kalpathi, Krishnamani Iyer, Gundeti, Sadashivudu, Rajappa, Senthil J., Digumarti, Raghunadharao, Paul, Tara Roshni, Tandon, Ashwani

“…Introduction: Childhood chronic myeloid leukemia (CML) accounts for less than 3% of all childhood leukemias, hence, data on imatinib (IM) in adult CML patients…”
Get full text

Prognostic significance of NLR kinetics in operable triple negative breast cancer by Ganta, Ranga Raman, Nasaka, Srividya

“…Abstract only e14201 Background: Inflammatory response exacerbates mechanisms linked to tumor growth and dissemination. As an index of systemic inflammatory…”
Get full text

Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia - Chronic Phase by Ganta, Ranga Raman, Nasaka, Srividya, Gundeti, Sadashivudu

“…The authors aimed to study the impact of adherence to imatinib during initial 6 mo on the cytogenetic response in pediatric chronic myeloid leukemia - chronic…”
Get full text

Induction chemotherapy with nanosomal docetaxel lipid suspension (NDLS), cisplatin, and fluorouracil in patients with locally advanced head and neck squamous cell carcinoma by Biswas, Ghanashyam, Ganta, Ranga Raman, N, Kharthik, Kantharia, Rajesh, Bondarde, Shailesh, Raghu Raman, Ramaiyer, Mahajan, Manoj, Ahmad, Ateeq, Sheikh, Saifuddin, Ali, Shoukath M, Paithankar, Mahesh, Patel, Lav, Rajani, Anil, Bunger, Deepak, Chaturvedi, Alok, Ahmad, Imran

“…6074 Background: Nanosomal docetaxel lipid suspension (NDLS), a polysorbate-80 and ethanol free formulation, was developed to overcome the toxicity issues and…”
Get full text

Effectiveness in Predicting the Response and Outcome with Three Prognostic Scoring Systems in Pediatric CML CP on Upfront Imatinib by Raman, Ganta Ranga, Nasaka, Srividya, Gundeti, Sadashivudu, Linga, Vijay Gandhi, Anukonda, Narendra, krishna Mani, Kkv, Srinivas, Laxmi

“…▪ Introduction: The Sokal and Hasford (Euro) scores were developed in the chemotherapy and interferon era and are widely used as prognostic indicators in…”
Get full text

Imatinib dose hike in suboptimal response and failure in CML CP: Results from a developing nation by Gullipalli, Muralidhar, Linga, Vijay Gandhi, Kota, Rajesh, Kalpathi, Krishnamani, Maddi, Rahul Narayan, Goteke, Vamshi Krishna Reddy, Arigela, Ravi Sankar, Nasaka, Srividya, Ganta, Ranga Raman, Gundeti, Sadashivudu, Digumarti, Raghunadharao

“…Abstract only e18003 Background: As perEuropean Leukemia Net (ELN) guidelines Imatinib 400mg/day is the standard of care in CML-CP. Options for patients with…”
Get full text

Is rituximab-based chemotherapy a standard practice in the treatment of B-NHLs in the developing world by Kota, Rajesh, Linga, Vijay Gandhi, Gullipalli, Muralidhar, Kalpathi, Krishnamani, Goteke, Vamshi Krishna Reddy, Maddi, Rahul Narayan, Ganta, Ranga Raman, Arigela, Ravi Sankar, Nasaka, Srividya, Gundeti, Sadashivudu, Digumarti, Raghunadharao

“…Abstract only e19533 Background: B Non Hodgkin Lymphoma (B-NHL) constitutes 90% of all NHLs. Surface CD20 is expressed in most of them. Standard of care…”
Get full text

Effectiveness of Three Prognostic Scoring Systems in Predicting the Response and Outcome in Pediatric Chronic Myeloid Leukemia Chronic Phase on Frontline Imatinib by Ganta, Ranga Raman, Nasaka, Srividya, Linga, Vijay Gandhi, Gundeti, Sadashivudu, Maddali, Lakshmi Srinivas, Digumarti, Raghunadha Rao

“…The Sokal and Hasford (Euro) scores were developed in the chemotherapy and interferon eras and are widely used as prognostic indicators in patients with…”
Get full text

Outcomes of Ewing’s sarcoma: Real-world scenario from the developing world—An 11-year analysis by Nasaka, Srividya, Ganta, Ranga Raman, Arigela, Ravi Sankar, Kalpathi, Krishnamani Iyer, Kota, Rajesh, Gullipalli, Muralidhar, Kagita, Sailaja, Pillai, Ashok Kumar, Kandula, Ramu, Bala, Joseph Stalin, Linga, Vijay Gandhi, Gundeti, Sadashivudu, Maddali, Lakshmi S., Digumarti, Raghunadharao

“…Abstract only…”
Get full text

Outcomes in pediatric CML in a developing country: Beyond the disease biology by Ganta, Ranga Raman, Gundeti, Sadashivudu, Nasaka, Srividya, Linga, Vijay Gandhi, Arigela, Ravi Sankar, Kota, Rajesh, Kalpathi, Krishnamani Iyer, Gullipalli, Muralidhar, Pillai, Ashok Kumar, Kandula, Ramu, Bala, Joseph Stalin, Maddali, Lakshmi S., Digumarti, Raghunadharao

“…Abstract only…”
Get full text

Impact of treatment protocol on outcome of localized Ewing′s sarcoma by Srividya Nasaka, Sadashivudu Gundeti, Ranga Raman Ganta, Ravi Sankar Arigela, Vijay Gandhi Linga, Lakshmi Srinivas Maddali

“…Background: The outcome of localized Ewing′s sarcoma has improved with multi-disciplinary approach. Survivals of Ewing′s sarcoma from the Asian countries…”
Get full text

Trends in management of acute lymphoblastic leukemia: Influence of insurance based healthcare and treatment compliance on the outcome of adolescents and adults with acute lymphoblastic leukemia by Arigela, Ravi Sankar, Gundeti, Sadashivudu, Ganta, Ranga Raman, Nasaka, Srividhya, Linga, Vijay Gandhi, Maddali, Lakshmi Srinivas

“…In this study, we attempted to analyze the impact of insurance based health care system and treatment compliance on the outcome of adolescent and adults with…”
Get full text

Impact of treatment protocol on outcome of localized Ewing’s sarcoma by Nasaka, Srividya, Gundeti, Sadashivudu, Ganta, Ranga Raman, Arigela, Ravi Sankar, Linga, Vijay Gandhi, Maddali, Lakshmi Srinivas

“…Abstract Background: The outcome of localized Ewing′s sarcoma has improved with multi-disciplinary approach. Survivals of Ewing′s sarcoma from the Asian…”
Get full text

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase: In pursuit of perfection by Linga, Vijay Gandhi, Ganta, Ranga Raman, Kalpathi, Krishnamani Iyer, Gundeti, Sadashivudu, Rajappa, Senthil J., Digumarti, Raghunadharao, Paul, Tara Roshni, Tandon, Ashwani

“…Abstract Introduction: Childhood chronic myeloid leukemia (CML) accounts for less than 3% of all childhood leukemias, hence, data on imatinib (IM) in adult CML…”
Get full text